Albany, NY -- (SBWire) -- 08/17/2017 --According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings. Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition.

The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.

The global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.

Click to get sample PDF with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=892950

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Browse more details at: http://www.researchmoz.us/global-next-generation-biologics-market-2016-2020-report.html

Key vendors
- F. Hofmann-La Roche
- Novo Nordisk
- Sanofi
- Takeda Pharmaceuticals

Other prominent vendors
- Aastrom Biosciences
- AbbVie
- AbGenomics
- Acologix
- ADC Therapeutics
- Adocia
- Agensys
- AlloCure
- AlloSource
- ALMAC Group
- Alphatec Spine
- Ambrx
- Amorcyte
- Argos Therapeutics
- Astellas Pharma
- AstraZeneca
- Athersys
- Avita Medical

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG